APP and Alzheimer disease: In this regard, antagonism of the TP receptor has been suggested as a potential strategy to reduce Aβ production in AD, as activation of this receptor by iPF2αIII or TXA2 results in increased APP mRNA and APP protein expression, as well as elevated Aβ release11, 12.